...
首页> 外文期刊>Nature >PREVENTION AND REVERSAL OF RENAL ALLOGRAFT REJECTION BY ANTIBODY AGAINST CD45RB
【24h】

PREVENTION AND REVERSAL OF RENAL ALLOGRAFT REJECTION BY ANTIBODY AGAINST CD45RB

机译:抗CD45RB抗体预防和逆转同种异体肾移植

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

REJECTION continues to be the single largest impediment to successful organ transplantation(1). Antilymphocyte globulin, which contains antibodies that react with the leukocyte common antigen known as CD45 (refs 2-6), has proved to be one of the most effective agents for preventing rejection. We have shown earlier that a monoclonal antibody directed against the RB isoform of CD45 substantially inhibits the alloreactivity of human CD4(+) lymphocytes in vitro(7). Here we investigate whether CD45RB could be an appropriate target for preventing renal allograft rejection in mice. Mice treated with two injections of a monoclonal antibody (MB23G2) (ref. 8) raised against CD45RB protein all survived and had normal renal function. Furthermore, this antibody reversed acute rejection when therapy was delayed until day 4, and the mice survived for their natural lifespan. The immunosuppression achieved may find application in the prevention and treatment of transplant rejection in man. [References: 15]
机译:拒绝仍然是成功器官移植的最大障碍(1)。抗淋巴细胞球蛋白含有与白细胞常见抗原CD45反应的抗体(参考文献2-6),已被证明是预防排斥的最有效药物之一。我们先前已经表明,针对CD45的RB亚型的单克隆抗体在体外可显着抑制人CD4(+)淋巴细胞的同种异体反应(7)。在这里,我们调查CD45RB是否可能是预防小鼠肾脏同种异体移植排斥的合适靶标。用两次注射针对CD45RB蛋白的单克隆抗体(MB23G2)(参考文献8)治疗的小鼠全部存活,并且肾功能正常。此外,当治疗推迟至第4天时,该抗体可以逆转急性排斥反应,小鼠可以自然生存。所获得的免疫抑制可用于预防和治疗人类移植排斥。 [参考:15]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号